Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tasquinimod - Active Biotech

Next Previous
Drug Profile

Tasquinimod - Active Biotech

Alternative Names: ABR-215050; TASQ

Latest Information Update: 27 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Active Biotech
  • Developer Active Biotech; Ipsen; University of Pennsylvania
  • Class Amides; Antineoplastics; Fluorinated hydrocarbons; Quinolines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Calgranulin B modulators; Immunomodulators; Thrombospondin 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Myelofibrosis
  • New Molecular Entity Yes
  • Available For Licensing Yes - Multiple myeloma

Highest Development Phases

  • Phase II Myelofibrosis
  • Phase I/II Multiple myeloma
  • Preclinical Acute myeloid leukaemia; Myelodysplastic syndromes
  • Discontinued Gastric cancer; Liver cancer; Ovarian cancer; Prostate cancer; Renal cancer

Most Recent Events

  • 18 Aug 2026 Active Biotech, Icahn School of Medicine and Myeloproliferative Neoplasms Research Consortium agree to co-develop tasquinimod for Myelofibrosis
  • 18 Aug 2026 Active Biotech in collaboration with Icahn School of Medicine and Myeloproliferative Neoplasms Research Consortium plans a preclinical trial for Myelofibrosis in USA
  • 24 Jul 2026 EMA approves protocol amendment for phase Ib/II TasqForce trial in Myelofibrosis

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top